A pilot study suggests that the G/G genotype of resistin single nucleotide polymorphism at -420 may be an independent predictor of a reduction in fasting plasma glucose and insulin resistance by pioglitazone in type 2 diabetes.
The aim of this study was to determine the relation between the G/G genotype of a resistin gene promoter single nucleotide polymorphism (SNP) at -420 (rs1862513) and glycemic control by pioglitazone in type 2 diabetes. In Study 1, 121 type 2 diabetic patients were treated with pioglitazone (15 or 30 mg/day) for 12 weeks, in addition to previous medication. In Study 2, 63 patients who had been treated with pioglitazone for 12 weeks were examined retrospectively. In Study 1, multiple regression analysis revealed that the G/G but not C/G genotype was correlated with a reduction in fasting plasma glucose (FPG) and homeostasis model assessment of insulin resistance (HOMA-IR) compared to C/C. When adjusted for age, gender, and BMI, the G/G genotype was an independent factor for the reduction of FPG (P=0.020) and HOMA-IR (P =0.012). When studies 1 and 2 were combined by adjusting the studies, age, gender, and BMI, the reduction of HbA1c was correlated with the G/G genotype (beta=-0.511, P=0.044). Therefore, this pilot study suggests that the G/G genotype of resistin SNP -420 may be an independent predictor of the reduction of fasting plasma glucose and HOMA-IR by pioglitazone.
Makino
Hideichi
H
Institute of Diabetes Research Center, Takanoko Hospital, Ehime, Japan. hidemak@takanoko-hsp.jp
Shimizu
Ikki
I
Murao
Satoshi
S
Kondo
Shiori
S
Tabara
Yasuharu
Y
Fujiyama
Masao
M
Fujii
Yasuhisa
Y
Takada
Yasuharu
Y
Nakai
Kazuaki
K
Izumi
Kenichi
K
Ohashi
Jun
J
Kawamura
Ryoichi
R
Yamauchi
Junko
J
Takata
Yasunori
Y
Nishida
Wataru
W
Hashiramoto
Mitsuru
M
Onuma
Hiroshi
H
Osawa
Haruhiko
H
D000328:Adult; D000368:Aged; D001786:Blood Glucose / Q000032:analysis*; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy*; D005260:Female; D006442:Glycated Hemoglobin / Q000032:analysis; D006706:Homeostasis / Q000187:drug effects; D006720:Homozygote; D006801:Humans; D006943:Hyperglycemia / Q000517:prevention & control; D007004:Hypoglycemic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D007333:Insulin Resistance; D008297:Male; D008875:Middle Aged; D010597:Pharmacogenetics / Q000379:methods; D010865:Pilot Projects; D000077205:Pioglitazone; D020641:Polymorphism, Single Nucleotide; D011401:Promoter Regions, Genetic / Q000235:genetics*; D052243:Resistin / Q000097:blood / Q000235:genetics*; D012189:Retrospective Studies; D045162:Thiazolidinediones / Q000008:administration & dosage / Q000627:therapeutic use*; D016896:Treatment Outcome
D001786:Blood Glucose; D006442:Glycated Hemoglobin; D007004:Hypoglycemic Agents; D000077205:Pioglitazone; D052243:Resistin; D045162:Thiazolidinediones; C517652:hemoglobin A1c protein, human